|Articles|March 18, 2020
Three Key Critical Considerations Before Embarking on Decentralized Trials
Author(s)Oracle
- Clinical trials can be designed across a continuum of formats. - Adding decentralized elements to trials can help acquire high-quality data. - Sponsors must understand the impact across the trial landscape for success.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Related Content
Trending on PharmExec
1
Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade
2
Eli Lilly Enters $1.2 Billion Definitive Agreement to Acquire Ventyx Biosciences
3
FDA Limits Regulations on Non-Medical Grade Wearable Fitness Devices
4
FDA Sends Decision Letter to Vanda Pharmaceuticals for NDA of Hetlioz
5